Mesotherapy for hair loss is a minimally invasive procedure in which a cocktail of vitamins, minerals, amino acids, and sometimes prescription medicines is injected directly into the scalp to stimulate hair follicles. Originally developed in France in the 1950s, it has grown in popularity across UK aesthetic clinics as an adjunctive option for conditions such as androgenetic alopecia and telogen effluvium. However, the evidence base remains limited, several ingredients are used off-label, and the sector is not yet fully regulated in England. This guide explains how mesotherapy works, what the research shows, what to expect from treatment, and how to find a qualified practitioner.

What Is Mesotherapy and How Is It Used for Hair Loss?

Mesotherapy for hair loss involves delivering microinjections of vitamins, minerals, amino acids, and sometimes off-label prescription medicines into the scalp dermis to stimulate follicular activity, though proposed mechanisms remain theoretically rather than robustly evidenced.

Not sure if this is normal? Chat with one of our pharmacists →

Mesotherapy is a minimally invasive aesthetic procedure that involves delivering small quantities of active substances directly into the dermis via intradermal microinjections. Originally developed in France during the 1950s by Dr Michel Pistor, the technique has since been adapted for a wide range of cosmetic and medical applications, including the treatment of hair loss (alopecia).

When used for hair loss, mesotherapy typically involves a series of microinjections administered into the scalp, targeting the dermis overlying the hair follicles. The injected cocktail commonly contains a combination of:

• Vitamins (such as biotin and B-complex vitamins)

• Minerals (including zinc and iron)

• Amino acids and peptides

• Hyaluronic acid for hydration

• Minoxidil or other vasodilatory agents in some formulations

• Finasteride (used in certain clinics for male-pattern hair loss)

It is important to note that injectable minoxidil and injectable finasteride are not licensed for this route of administration in the UK. Their use in mesotherapy formulations is therefore unlicensed and off-label. This means they must be prescribed by an appropriate prescriber (such as a GMC-registered doctor), with clear informed consent and an explanation of the potential for systemic adverse effects — including cardiovascular effects with minoxidil and sexual or psychiatric effects with finasteride (see the MHRA Drug Safety Update on finasteride). Patients should be made aware of these risks before agreeing to any formulation containing these agents.

The rationale behind mesotherapy for hair loss is that delivering substances directly into the scalp may allow higher local concentrations to reach the hair follicle environment. However, it is important to understand that intradermal injections do not eliminate systemic absorption — active compounds can still enter the bloodstream, particularly when prescription-only medicines (POMs) are included. The proposed mechanisms — stimulating follicular activity, improving microcirculation, and reducing scalp inflammation — remain theoretical and are not yet robustly established by clinical evidence.

Mesotherapy has been used across a range of hair loss conditions, including androgenetic alopecia (the most common form, affecting both men and women), telogen effluvium, and alopecia areata. However, the evidence supporting its use varies considerably by condition and is weakest for telogen effluvium and alopecia areata. For alopecia areata in particular, established UK treatments such as intralesional corticosteroids (administered by a dermatologist) are better supported by evidence and are recommended in NICE guidance. Mesotherapy is generally considered a complementary or adjunctive option rather than a standalone treatment, and is typically offered as a course of sessions rather than a single procedure.

What Does the Evidence Say About Mesotherapy for Hair Loss?

The evidence for mesotherapy in hair loss is limited to small, methodologically weak studies; NICE does not recommend it as a first-line treatment, and no MHRA-licensed injectable products are specifically indicated for this use.

The evidence base for mesotherapy as a treatment for hair loss remains limited in scope and quality. The majority of published studies are small, heterogeneous, and methodologically weak, with few well-powered randomised controlled trials (RCTs) or adequately blinded placebo-controlled studies. This makes it difficult to draw firm conclusions about efficacy.

Some small-scale clinical studies and systematic reviews have reported positive outcomes — such as increased hair density, reduced shedding, and improved scalp condition — primarily in patients with androgenetic alopecia. A 2013 study published in the Journal of Cutaneous and Aesthetic Surgery reported statistically significant improvements in hair count compared to baseline, though it lacked a robust control group. More recent reviews have echoed these findings but consistently highlight the need for larger, well-designed RCTs before mesotherapy can be considered an evidence-based treatment.

The evidence is considerably weaker for telogen effluvium and alopecia areata. For alopecia areata, NICE guidance supports the use of intralesional corticosteroids and referral to dermatology; mesotherapy is not a recognised first-line option for this condition.

There are no MHRA-licensed injectable products specifically indicated for mesotherapy in hair loss, and NICE does not recommend mesotherapy as a first-line treatment for any form of alopecia. By contrast, topical minoxidil and oral finasteride (for men) have robust clinical trial data and established regulatory approval for androgenetic alopecia via their licensed routes of administration.

The wide variability in formulations, dosages, and injection techniques used across clinics — with no standardised, evidence-based protocol — further limits the comparability of existing studies and makes it difficult to assess overall efficacy or safety.

For patients considering mesotherapy, it is advisable to view it as an investigational or adjunctive option rather than a proven treatment. Before pursuing any aesthetic intervention, patients should seek assessment from a GP or dermatologist to identify any underlying medical cause of hair loss. Relevant investigations may include a full blood count, ferritin, thyroid function tests (TSH), and assessment for autoimmune conditions, in line with NICE CKS guidance on female pattern hair loss and alopecia areata. The NHS provides patient-facing information on hair loss and when to seek medical advice.

What to Expect During and After Treatment in the UK

Mesotherapy is a private, self-funded procedure typically delivered in weekly or fortnightly sessions over 4–8 weeks, with results — if they occur — usually gradual and assessed after 3–6 months.

In the UK, mesotherapy for hair loss is typically offered by aesthetic clinics, private dermatology practices, and some trichology centres. It is not routinely available on the NHS and is almost always a self-funded, private procedure. Before undergoing treatment, a reputable practitioner should conduct a thorough consultation, which may include a review of your medical history, an assessment of your hair loss pattern, and in some cases a trichoscopy (a non-invasive scalp examination using a dermatoscope).

The procedure itself usually takes between 30 and 60 minutes per session. A fine needle or a specialised mesotherapy device is used to administer multiple small injections across the scalp using aseptic technique and single-use sterile needles. Most practitioners apply a topical anaesthetic cream beforehand to minimise discomfort, though patients commonly report a mild stinging or pressure sensation during the injections. The scalp may appear slightly red or feel tender immediately afterwards.

A typical treatment course in the UK might look like this:

• Initial phase: Weekly or fortnightly sessions for 4–8 weeks

• Maintenance phase: Monthly sessions thereafter, depending on response

• Review: Progress is usually assessed after 3–6 months, often using photographic comparison or trichoscopy

It should be noted that there is no standardised, evidence-based treatment regimen for mesotherapy in hair loss; schedules vary between providers and are not derived from robust clinical protocols.

After each session, patients are generally advised to:

• Avoid washing their hair for 24 hours

• Refrain from vigorous exercise for 24 hours

• Avoid swimming, saunas, and steam rooms for 24–48 hours

• Avoid direct sun exposure to the scalp

• Avoid alcohol-based scalp products or topicals for 24–48 hours

Visible results, if they occur, are typically gradual — most patients who respond to treatment notice improvements in hair texture and reduced shedding before any increase in density becomes apparent. Realistic expectations are essential, and practitioners should communicate clearly that individual responses vary considerably and that a positive outcome cannot be guaranteed.

Possible Side Effects and Safety Considerations

Common side effects are mild and transient, but serious risks include infection, anaphylaxis, and systemic cardiovascular or psychiatric effects when prescription-only medicines such as minoxidil or finasteride are included in the formulation.

Experiencing these side effects? Our pharmacists can help you navigate them →

Mesotherapy is generally considered a low-risk procedure when performed by a trained and experienced practitioner using aseptic technique, single-use sterile equipment, and pharmaceutical-grade products from regulated suppliers. However, as with any injectable treatment, there are potential side effects and safety considerations that patients should be aware of before proceeding.

Common side effects are usually mild and transient, and may include:

• Redness, swelling, or bruising at injection sites

• Temporary scalp tenderness or itching

• Small bumps or wheals that resolve within a few hours

• Mild headache following the procedure

• Vasovagal syncope (fainting) during or shortly after the procedure

Less common but more serious risks include:

• Infection, including folliculitis or abscess — particularly if non-sterile technique or unregulated products are used

• Allergic reaction to one or more components in the injected cocktail, ranging from localised reactions to anaphylaxis

• Granuloma formation at injection sites

• Scarring or skin necrosis in rare cases, typically associated with poor technique

• Hyperpigmentation or hypopigmentation at injection sites, which may persist — more commonly seen in individuals with darker skin tones

Systemic adverse effects are an additional concern when prescription-only medicines are included in the formulation. If finasteride is used, patients should be aware of the risk of sexual dysfunction and psychiatric side effects (including depression), as highlighted in the MHRA Drug Safety Update on finasteride. If minoxidil is included, systemic absorption may cause cardiovascular effects such as hypotension or tachycardia. These risks should be discussed in full before treatment, and use of such agents requires prescribing by an appropriate prescriber with documented informed consent.

A key safety concern in the UK context is the use of unlicensed or unregulated mesotherapy products. Some formulations available online or used in unregulated settings may contain substances not approved for injectable use. Patients are strongly advised to ask their practitioner to confirm the source, regulatory status, and full ingredient list of all products used.

What to do if you experience a problem:

• Call 999 immediately if you experience signs of anaphylaxis — such as difficulty breathing, throat tightening, widespread rash, or facial swelling

• Contact NHS 111 for urgent but non-life-threatening concerns, such as signs of infection (increasing redness, warmth, pus, or fever) or unusual symptoms following treatment

• Contact your GP if you have ongoing concerns about your recovery or any unexpected changes

Patients are also encouraged to report any suspected side effects from products used during mesotherapy via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. This helps the MHRA monitor the safety of medicines and medical devices used in the UK.

Those who are pregnant, breastfeeding, have active scalp infections or inflammatory scalp conditions, or are taking anticoagulant medications should discuss their suitability for mesotherapy with a healthcare professional before proceeding.

Finding a Qualified Practitioner in the UK

Patients should seek a GMC-, NMC-, GDC-, or GPhC-registered practitioner listed on a PSA-accredited register such as JCCP or Save Face, as aesthetic injectables in England are not yet subject to mandatory statutory regulation.

One of the most important steps when considering mesotherapy for hair loss in the UK is ensuring that the practitioner delivering the treatment is appropriately qualified and working within a regulated environment. Unlike some medical procedures, aesthetic treatments including mesotherapy are not currently subject to mandatory statutory regulation in England, which means that — in theory — anyone can offer injectable treatments without formal medical training. This makes due diligence on the part of the patient especially important.

When searching for a practitioner, look for the following:

• Medical or clinical qualifications: Ideally, your practitioner should be a doctor (GMC-registered), nurse (NMC-registered), dentist (GDC-registered), or pharmacist (GPhC-registered) with specific training in aesthetic medicine. You can verify registration numbers on the relevant regulatory body's website

• Prescribing oversight: If the formulation includes prescription-only medicines such as finasteride or minoxidil, these must be prescribed by an appropriate prescriber following a clinical assessment, with documented informed consent and an explanation of the risks of off-label use

• Membership of professional bodies: Organisations such as the British College of Aesthetic Medicine (BCAM) or the Aesthetic Complications Expert (ACE) Group can indicate a commitment to professional standards

• PSA-accredited voluntary registers: The Joint Council for Cosmetic Practitioners (JCCP) and Save Face are accredited by the Professional Standards Authority (PSA) and maintain registers of practitioners who meet defined standards of training, insurance, and accountability. Checking these registers is a practical step towards finding a safer provider

• Transparent consultation process: A reputable clinic will offer a thorough pre-treatment consultation, provide written information about the procedure, obtain documented informed consent, and be willing to answer questions about the products used

• Use of licensed, traceable products: Ask specifically about the products being used, their regulatory status, and whether they are sourced from regulated pharmaceutical suppliers

A note on trichologists: Trichologists specialise in hair and scalp health, but many are not medically qualified and cannot prescribe medicines. If your hair loss may have an underlying medical cause, or if prescription treatments are being considered, assessment by a GMC-registered dermatologist is advisable.

Regulatory developments: The Health and Care Act 2022 introduced provisions for the licensing of non-surgical cosmetic procedures in England. Policy responsibility for implementing these changes sits with the Department of Health and Social Care (DHSC). Further details on the licensing framework and timelines are available via GOV.UK. These changes are expected to strengthen patient protections in the aesthetic sector in the coming years.

If you are uncertain where to begin, your GP is a valuable first point of contact. They can help rule out underlying medical causes of hair loss — including thyroid dysfunction, nutritional deficiencies, and autoimmune conditions — and, where appropriate, refer you to an NHS or private dermatologist for specialist assessment before you consider aesthetic treatments such as mesotherapy.

Frequently Asked Questions